Intuitive Surgical stock holds near $398 as Q2 2026 growth stays in double digits
Published on 08/20/2026 at 09:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Intuitive Surgical Inc. (ISIN US46120E6023) stock is consolidating just below $400 as of August 19, 2026, while the company backs up its premium valuation with double-digit growth in robotic procedures and revenue in the second quarter of 2026. Recent coverage of its latest earnings recap highlights that worldwide da Vinci procedure volumes grew 16 percent and total revenue increased 19 percent year over year in the period ended June 30, 2026.
Q2 2026 shows robust growth in procedures and revenue
In mid-July 2026, Intuitive Surgical released second-quarter results for the period ending June 30, 2026, giving investors a detailed look at how its robotic-surgery business is performing under macroeconomic and competitive pressure. A recent second-quarter earnings overview covering that period reports that worldwide da Vinci procedure growth reached 16 percent, while total revenue climbed 19 percent year over year, signaling broad-based demand for the companys systems and recurring instruments.
The same Q2 2026 recap explains that hospitals continued to ramp up usage of da Vinci systems during the quarter, with the installed base supporting higher instrument and accessories revenue as procedures rise. That mix of procedure expansion and recurring revenue growth suggests that Intuitive Surgical is still in a scale-up phase, even as the stock price has retreated from early-2026 highs.
Guidance for 2026 da Vinci procedures supports the outlook
The earnings coverage notes that management set full-year 2026 guidance for da Vinci procedure growth in a range of 13.5 percent to 15.5 percent, anchoring expectations for the rest of the year. That range compares with the 16 percent worldwide procedure growth delivered in the second quarter of 2026, indicating that management is planning for growth to normalize modestly from the Q2 pace but remain solidly in double-digit territory.
Recent analysis of Intuitive Surgicals positioning stresses that the updated guidance range means 2026 procedure growth could end up close to the midpoint, reinforcing the message that hospitals are still expanding robotic-surgery usage. For investors, the key comparison is that the 13.5 percent to 15.5 percent full-year range is slightly lower than the 16 percent achieved in the second quarter of 2026, but still points to a healthy expansion pipeline as new systems are installed and existing systems are used more intensively.
Stock trades well below early-2026 levels despite growth
A detailed market-data summary dated August 18, 2026 states that Intuitive Surgical stock closed at $391.18 on the Nasdaq on August 18, 2026 at 4:00 p.m. ET, with extended trading quotes later that evening indicating a modest uptick to $391.50. That same overview places the shares within a short-term trading band between $390.24 and $394.51 in mid-August 2026, highlighting contained day-to-day volatility as the market digests the companys new guidance and recent regulatory milestones.
The same market-data coverage underlines that as of August 18, 2026 the stock level around $391.18 leaves Intuitive Surgical shares roughly 30 percent below their early-2026 level above $560. The comparison also shows the shares trading well under a reported 52-week high of $496.48 even as second-quarter 2026 procedures grew 16 percent and revenue increased 19 percent year over year, underscoring the reset in expectations that has occurred in 2026.
Another recent quote and analysis source updated on August 19, 2026 reports that Intuitive Surgical shares were at $397.72 as of the latest close, representing a short-term advance of 12.61 percent over the prior 30 days but a year-to-date decline of 29.23 percent. That same overview cites a fair-value narrative placing intrinsic value at $630.48 per share, well above the last close of $397.72, illustrating how some valuation models continue to see upside even after the drawdown in 2026.
Consensus view and valuation context
One recent stock-analysis page dated August 20, 2026 points out that Intuitive Surgical shares traded at $399.56, with an intraday quote of $400.23 at 11:43 a.m. Eastern time on that date and a daily gain of 2.31 percent at that intraday snapshot. The same data indicates that Intuitive Surgical stock was trading at $566.36 at the beginning of 2026 and has since decreased by 29.5 percent to reach $399.56, consistent with other reports of a roughly 30 percent year-to-date decline.
The same analytical overview highlights a consensus rating for Intuitive Surgical described as a moderate buy, with an average price target of $508.68 per share. Against a current level of $399.56, that average target implies an upside potential of 27.3 percent, offering a concrete quantified comparison between where the stock is trading in late August 2026 and where covering analysts expect it could trade over their typical 12-month horizon.
An additional report on institutional activity notes that shares of Nasdaq-listed Intuitive Surgical opened at $391.18 on a recent trading session in August 2026, aligning with other quote data for that week. Within that same context, the consensus view combines 22 buy ratings, 8 hold ratings, and 1 sell rating, resulting in an average rating score of 2.68 on a scale where lower scores correspond to stronger recommendations, further emphasizing that sentiment remains broadly constructive even after the drawdown.
Market capitalization and longer-term performance
A separate analysis dated August 19, 2026 underscores that Intuitive Surgical currently has a market capitalization of $137.90 billion at recent prices, anchoring its status as one of the larger players in the medical-technology and robotic-surgery space. That capitalization figure, combined with the year-to-date decline of roughly 29 percent, shows how much market value has come off since the start of 2026 even though the underlying business continues to grow.
A feature article on the stocks performance in 2026 notes that Intuitive Surgical is down 33 percent for the year so far, even though it has delivered an average annual share-price gain of 17 percent over the past decade. That comparison highlights how the 2026 drawdown follows a long period of strong compounding returns, and it suggests that the current year is unusual relative to the companys longer-term track record.
The combination of a $137.90 billion market capitalization, a roughly 29 to 33 percent decline in 2026 year to date depending on the precise reference point, and continued double-digit growth in procedures and revenue means that valuation has compressed from earlier peaks. Some coverage points to fair-value estimates in the low $600s per share, meaning that the current price in the high $390s to low $400s stands well below those model-based targets.
Procedure guidance and competitive dynamics
In addition to the 13.5 percent to 15.5 percent full-year 2026 guidance range for da Vinci procedure growth, recent commentary compares Intuitive Surgicals premium-growth profile with other healthcare and medtech companies that emphasize steadier, more diversified growth trajectories. This comparison frames Intuitive Surgical as a company that historically delivered faster growth, but now faces a more mature installed base and rising competition in certain procedure categories.
Within that debate, the key figures that stand out are the 16 percent worldwide procedure growth in the second quarter of 2026 and the 13.5 percent to 15.5 percent full-year guidance range, indicating that management is not signaling a collapse in demand but rather a measured deceleration from a very strong recent quarter. For investors, the difference between 16 percent and a midpoint around 14.5 percent can matter for valuation models, as it informs expectations around instrument and accessories revenue and capital spending on new systems.
Some recent articles also point to regulatory and competitive factors shaping the outlook for Intuitive Surgical, including new entrants in robotic surgery and evolving reimbursement policies. While those pieces focus more on qualitative context than on hard numbers, they generally treat Intuitive Surgicals double-digit procedure growth and 19 percent revenue growth in the second quarter of 2026 as evidence that the company retains a strong competitive position despite the growing field.
Manufacturing expansion in Asia-Pacific
Beyond earnings, Intuitive Surgical has also been expanding its manufacturing footprint in the Asia-Pacific region, reflecting its strategy to support growing demand for robotic-surgery systems outside the United States. A recent update dated August 19, 2026 notes that Intuitive Surgical currently has a market capitalization of $137.90 billion and underscores that the companys expansion in Asia-Pacific manufacturing is intended to improve supply-chain resilience and support regional growth.
For investors, the combination of an enlarged manufacturing base and strong procedure growth may help support volume growth as the company continues to roll out its latest system generation and expands into new surgical specialties. The expansion also aligns with the guidance range for 2026 procedures, as increased regional capacity can help fulfill demand in countries where adoption is still ramping up.
da Vinci 5 and technology platform evolution
Several recent analyses highlight that Intuitive Surgical is rolling out its newest generation of robotic-surgery platform, often referred to as da Vinci 5, which places more emphasis on software and data. A separate corporate-news piece notes that the company has secured important regulatory clearances for new applications, including cardiac-related uses, reinforcing the perception that da Vinci 5 could open new procedure categories over time.
The same coverage indicates that the launch of da Vinci 5 is occurring against a backdrop of share-price volatility, with Intuitive Surgical stock consolidating around a new lower plateau in the high $390s to low $400s. That juxtaposition between technological progress and a lower share price than at the start of 2026 is one reason some valuation models estimate fair value above $600 per share while the current market price remains under $400.
As the company leans into a more software-centric platform with da Vinci 5, it continues to emphasize recurring revenue from instruments, accessories, and service, which scales with procedure volume. The 16 percent procedure growth and 19 percent revenue growth in the second quarter of 2026 are consistent with that model, since rising utilization of installed systems typically delivers higher-margin recurring revenue streams.
Representative product - the da Vinci surgical system
Intuitive Surgicals flagship product line is the da Vinci surgical system, a family of robotic platforms designed to enable minimally invasive surgery across multiple specialties. The systems allow surgeons to control robotic arms from a console, with high-definition visualization and precision instruments that can translate small hand movements into fine surgical actions inside the body.
Hospitals typically invest in da Vinci systems to perform procedures in areas such as urology, gynecology, general surgery, thoracic surgery, and increasingly other specialties as indications expand. The installed base of da Vinci systems generates recurring revenue as hospitals purchase instruments and accessories for each procedure, and the 16 percent growth in worldwide procedures in the second quarter of 2026 underscores how utilization helps drive Intuitive Surgicals top line.
Current stock level on Nasdaq
As of August 19, 2026, one recent market-data snapshot reports Intuitive Surgical stock at $397.72 at the close, with a 30-day share-price return of 12.61 percent and a year-to-date decline of 29.23 percent. Another snapshot tied to August 18, 2026 cites a closing price of $391.18 and a market capitalization of $138.57 billion at that level, while a separate data page notes an intraday quote of $400.23 and a contemporaneous price of $399.56 on August 20, 2026.
Taken together, these figures suggest that Intuitive Surgical stock is currently trading in a band between roughly $391 and $400 as of the most recent trading sessions in mid to late August 2026, down significantly from its early-2026 level of $566.36 but still commanding a triple-digit share price that reflects its leadership in robotic-assisted surgery. The shares continue to trade on the Nasdaq in U.S. dollars, with liquidity supported by their inclusion in major U.S. healthcare and growth indices.
Read more
Further corporate coverage on Intuitive Surgical stock and da Vinci 5
Fact box
Company: Intuitive Surgical Inc.
ISIN: US46120E6023
Ticker: ISRG
Exchange: Nasdaq
Price (as of August 19, 2026, 4:00 p.m. ET): $397.72 USD
Market cap: $137.90 billion (as of August 19, 2026)
Sector / Industry: Health Care / Health Care Equipment
Index membership: S&P 500
